Novo Nordisk (NVO) Operating Income by Segment

Shows the profitability of different business segments, highlighting which areas are driving Novo Nordisk's earnings and where there might be opportunities or challenges.

• Rare Disease
• Diabetes and Obesity Care
• Stock Price

Diabetes & Obesity Care has become the dominant and rapidly expanding profit engine, driving most of Novo Nordisk’s operating income, while Rare Disease is a small, volatile swing factor with occasional negative quarters—likely from one‑offs, launch investments or impairments. The sharp sequential dip and rebound in late‑2025 point to timing, pricing or inventory effects rather than secular weakness, but the concentration in GLP‑1 products raises sustainability risk: watch payer access, competition and margin guidance for lasting upside or pressure.